VEKLURY DIN 02502143
Health Canada record
| Active ingredient(s) | REMDESIVIR 100 MG |
|---|---|
| Dosage form | Powder For Solution |
| Route | Intravenous |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | J05AB16 REMDESIVIR |
| Original market date | 16-Oct-2020 |
| Current status date | 16-Oct-2020 |
| Source | Health Canada DPD |
Establishment licence of the holder
Gilead Sciences Canada Inc — licence 101221, currently licensed, last inspection rating C (2022-09-20).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing REMDESIVIR
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02502135 | VEKLURY | GILEAD SCIENCES CANADA INC | Solution | REMDESIVIR 100 MG | Cancelled Pre Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 23963 | 2020-07-27 | New Drug Submission (NDS) |
International API supply for REMDESIVIR
2 active FDA Drug Master Files.
Request a quote for VEKLURY